Delcath Systems, Inc. (NASDAQ:DCTH) Stock Has Consensus Price Target of $23.17 According to Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $23.17.

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. BTIG Research upped their target price on Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Weiss Ratings raised shares of Delcath Systems from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Finally, Zacks Research lowered shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th.

Institutional Trading of Delcath Systems

Several large investors have recently modified their holdings of DCTH. Bank of New York Mellon Corp acquired a new position in Delcath Systems in the 2nd quarter valued at $1,362,000. Integrated Wealth Concepts LLC bought a new position in Delcath Systems in the 2nd quarter worth $48,000. IFP Advisors Inc acquired a new position in Delcath Systems during the 2nd quarter worth $52,000. Bank of America Corp DE lifted its position in Delcath Systems by 54.0% during the 1st quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock worth $536,000 after acquiring an additional 20,249 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after acquiring an additional 2,364 shares during the last quarter. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Performance

DCTH opened at $15.67 on Tuesday. The company has a market cap of $543.75 million, a PE ratio of 1,568.57 and a beta of 0.60. The stock has a 50-day moving average of $16.08 and a 200-day moving average of $13.04. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The business had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. On average, research analysts predict that Delcath Systems will post -0.17 earnings per share for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc is a commercial-stage oncology company focused on liver-directed therapies for patients with metastatic cancer. Its technology is designed to deliver high concentrations of chemotherapy directly to the liver while limiting systemic exposure, addressing cancers that are difficult to treat with conventional approaches.

The company’s primary products are HEPZATO (melphalan for injection) and the HEPZATO KIT in the United States, as well as CHEMOSAT in markets outside the United States.